Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21827126 | 0.85 | APLNR (0.54) | APLNRTP53MAPTMEN1KMT2A | |
| SCHEMBL28452492 | 0.84 | APLNR (0.63) | APLNRTP53MAPTMEN1KMT2A | |
| SCHEMBL28970344 | 0.81 | APLNR (0.58) | APLNRTP53MAPTTSHRHTR2A | |
| SCHEMBL1530735 | 0.80 | APLNR (0.65) | APLNRTP53MEN1KMT2ATSHR | |
| SCHEMBL28923208 | 0.79 | APLNR (0.59) | APLNRTP53MAPTMEN1KMT2A | |
| SCHEMBL12494016 | 0.78 | ALDH1A1 (0.62) | APLNRTP53MAPTMEN1KMT2A | |
| SCHEMBL20530830 | 0.77 | APLNR (0.54) | APLNRTP53MAPTTSHRHTR2A | |
| SCHEMBL22537209 | 0.77 | APLNR (0.57) | APLNRTP53MAPTMEN1KMT2A | |
| SCHEMBL22537210 | 0.77 | APLNR (0.54) | APLNRTP53MEN1KMT2ATSHR | |
| SCHEMBL11300017 | 0.77 | TP53 (0.55) | APLNRTP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| WO-2025011684-A2 | N-SULFONAMIDE NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND APPLICATION THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | TP53, NPM1, TP53BP1 | APLNR 4229/4885TP53 1/4885MAPT 3898/4885 |
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NPM1 | APLNR 4305/4885TP53 1/4885MAPT 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.